AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 113806 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia with naloxone
Number of subjects: 10
Study 113806 — intervention group
Group type: COMPARATOR
Intervention: Hypnotic analgesia with placebo
Number of subjects: 10
Study 113806 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress with naloxone
Number of subjects: 10
Study 113806 — intervention group
Group type: COMPARATOR
Intervention: Stress with placebo
Number of subjects: 10
Study 113806 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety measures
Number of subjects: 10
Study 6357258 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of penbutolol and frusemide
Number of subjects: 41
Study 6357258 — intervention group
Group type: COMPARATOR
Intervention: Penbutolol alone
Number of subjects: 41
Study 6357258 — intervention group
Group type: COMPARATOR
Intervention: Frusemide alone
Number of subjects: 41
Study 31340789 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strains Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, administered orally (one capsule daily) until negative HR-HPV testing.
Number of subjects: 121
Study 31340789 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation, administered orally (one capsule daily) until negative HR-HPV testing.
Number of subjects: 121
Study 31340789 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic strains Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14
Number of subjects: 121
Study 31340789 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 121
Study 30003583 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical debridement with bone substitute (Endobon®)
Number of subjects: 41
Study 30003583 — intervention group
Group type: COMPARATOR
Intervention: Surgical debridement (control group)
Number of subjects: 41
Study 26779915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with vaginal spheres (spheres group)
Number of subjects: 70
Study 26779915 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training without vaginal spheres (control group)
Number of subjects: 70
Study 26779915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (both groups)
Number of subjects: 70
Study 24949949 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 0
Study 24949949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22974092 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan with the Nordic bolus 5‐fluorouracil (5‐FU) and folinic acid schedule (FLIRI)
Number of subjects: 106
Study 22974092 — intervention group
Group type: EXPERIMENTAL
Intervention: de Gramont schedule (Lv5FU2‐IRI)
Number of subjects: 106
Study 22974092 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in tumor marker levels during treatment
Number of subjects: 106
Study 21990564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) with up to 0.9 mg/kg alteplase over 60 min
Number of subjects: 54
Study 21990564 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT) with alteplase according to European labeling
Number of subjects: 54
Study 21990564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT)
Number of subjects: 54
Study 21990564 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 54
Study 18585499 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP testing (n = 241)
Number of subjects: 477
Study 15589080 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Care (SC) cohort
Number of subjects: 44
Study 15589080 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) cohort
Number of subjects: 44
Study 11134261 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiled dialysate sodium and ultrafiltration
Number of subjects: 33
Study 11134261 — intervention group
Group type: EXPERIMENTAL
Intervention: Profiled treatments
Number of subjects: 33
Study 11134261 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 33
Study 8995117 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surveillance after ileorectal anastomosis or ileoanal pouch anastomosis
Number of subjects: 0
Study 8485825 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor treatment (specific drug not mentioned)
Number of subjects: 48
Study 8485825 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitor treatment (enalapril)
Number of subjects: 48
Study 8485825 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (5 mg) in patients with essential hypertension
Number of subjects: 48
Study 2892518 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 2 mg
Number of subjects: 160
Study 2892518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 1 mg
Number of subjects: 160
Study 2892518 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 1 mg
Number of subjects: 160
Study 2892518 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium-associated side effects prevention
Number of subjects: 160
Study 27824485 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin-enhanced MRCP
Number of subjects: 72
Study 27824485 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched subjects without recurrent acute pancreatitis or chronic pancreatitis)
Number of subjects: 72
Study 27096729 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-switched Nd:YAG laser
Number of subjects: 25
Study 27096729 — intervention group
Group type: COMPARATOR
Intervention: Fractional CO2 laser
Number of subjects: 25
Study 25062783 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaler reminders and feedback (IRF)
Number of subjects: 143
Study 25062783 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized adherence discussions (PADs)
Number of subjects: 143
Study 25062783 — intervention group
Group type: COMPARATOR
Intervention: Active usual care alone (Control)
Number of subjects: 143
Study 25062783 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall asthma control (all groups)
Number of subjects: 143
Study 22275291 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg or 10 mg/kg
Number of subjects: 0
Study 22275291 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 0
Study 22275291 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 0
Study 22275291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20530391 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated implementation approach
Number of subjects: 36
Study 20530391 — intervention group
Group type: COMPARATOR
Intervention: Self-directed implementation approach
Number of subjects: 36
Study 17975960 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatoplasty with CO2 laser
Number of subjects: 21
Study 17975960 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgical intervention)
Number of subjects: 21
Study 15802479 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based electronic reminders for diabetes care
Number of subjects: 6748
Study 15802479 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based electronic reminders for CAD care
Number of subjects: 6748
Study 15802479 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diabetes care compliance
Number of subjects: 6748
Study 15802479 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall CAD care compliance
Number of subjects: 6748
Study 15802479 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician attitudes toward the reminder system
Number of subjects: 6748
Study 15802479 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 6748
Study 12362115 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (100 units)
Number of subjects: 9
Study 12362115 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 9
Study 9881427 — intervention group
Group type: EXPERIMENTAL
Intervention: New system B
Number of subjects: 34
Study 9881427 — intervention group
Group type: EXPERIMENTAL
Intervention: New system C
Number of subjects: 34
Study 9881427 — intervention group
Group type: COMPARATOR
Intervention: Conventional system A
Number of subjects: 34
Study 9881427 — intervention group
Group type: EXPERIMENTAL
Intervention: All systems (A, B, C)
Number of subjects: 34
Study 8306547 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdialysis ethanol technique
Number of subjects: 6
Study 8306547 — intervention group
Group type: EXPERIMENTAL
Intervention: 133Xe clearance
Number of subjects: 6
Study 8306547 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol outflow/inflow ratio
Number of subjects: 6
Study 8306547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate glucose concentration
Number of subjects: 6
Study 2899390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg/day)
Number of subjects: 50
Study 2899390 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 50
Study 2899390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31394602 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 1.5 atmospheres absolute, >99% oxygen
Number of subjects: 143
Study 31394602 — intervention group
Group type: COMPARATOR
Intervention: Sham chamber sessions at 1.2 atmospheres absolute, room air
Number of subjects: 143
Study 29061154 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatrician-led admission avoidance hospital at home
Number of subjects: 0
Study 29061154 — intervention group
Group type: COMPARATOR
Intervention: Inpatient admission
Number of subjects: 0
Study 25142276 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point cane
Number of subjects: 30
Study 25142276 — intervention group
Group type: COMPARATOR
Intervention: Quad cane
Number of subjects: 30
Study 25142276 — intervention group
Group type: COMPARATOR
Intervention: Hemi-walker
Number of subjects: 30
Study 25089169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone group (standard therapy plus oxygen-ozone treatment)
Number of subjects: 50
Study 25089169 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy only)
Number of subjects: 50
Study 25089169 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone group
Number of subjects: 50
Study 25089169 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 22178175 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented ginseng (3g)
Number of subjects: 24
Study 22178175 — intervention group
Group type: COMPARATOR
Intervention: Non-fermented ginseng (3g)
Number of subjects: 24
Study 19387386 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g per day, 4 doses of 5 g per day)
Number of subjects: 17
Study 19387386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar in appearance and taste)
Number of subjects: 17
Study 17459899 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable-state sputa
Number of subjects: 104
Study 17459899 — intervention group
Group type: EXPERIMENTAL
Intervention: Exacerbation sputa
Number of subjects: 104
Study 17459899 — intervention group
Group type: COMPARATOR
Intervention: Overall findings
Number of subjects: 104
Study 14707941 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0
Study 14707941 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 0
Study 11803729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (100-1200 mg/day)
Number of subjects: 1358
Study 11803729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (400-800 mg/day)
Number of subjects: 1358
Study 11803729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 1358
Study 11803729 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (long-term study)
Number of subjects: 1358
Study 11803729 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1358
Study 11803729 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol
Number of subjects: 1358
Study 11803729 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1358
Study 9617983 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (220 mg every 8 hours)
Number of subjects: 12
Study 9617983 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg every 6 hours)
Number of subjects: 12
Study 9617983 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg every 12 hours)
Number of subjects: 12
Study 9617983 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg every 12 hours) with naproxen sodium
Number of subjects: 12
Study 9617983 — intervention group
Group type: COMPARATOR
Intervention: Lithium carbonate (300 mg every 12 hours) with acetaminophen
Number of subjects: 12
Study 9097765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% SDZ GLC-756 eye drops (n = 6)
Number of subjects: 24
Study 9097765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% SDZ GLC-756 eye drops (n = 6)
Number of subjects: 24
Study 9097765 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% SDZ GLC-756 eye drops (n = 12)
Number of subjects: 24
Study 9097765 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 24
Study 2532921 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (30 mg)
Number of subjects: 6
Study 2532921 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (30 mg) with ramipril (5 mg) pretreatment
Number of subjects: 6
Study 788889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, 10 mg/kg/day orally for 7-10 days every 28 days for 1 year
Number of subjects: 113
Study 788889 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy (Control)
Number of subjects: 113
Study 31729973 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐flux bicarbonate hemodialysis with vitamin E‐loaded dialyzers
Number of subjects: 18
Study 31729973 — intervention group
Group type: COMPARATOR
Intervention: Low‐flux bicarbonate hemodialysis
Number of subjects: 18
Study 31729973 — intervention group
Group type: COMPARATOR
Intervention: Hemodialfitration
Number of subjects: 18
Study 31729973 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 18
Study 28870954 — intervention group
Group type: EXPERIMENTAL
Intervention: Folfox 4
Number of subjects: 48
Study 28870954 — intervention group
Group type: COMPARATOR
Intervention: de Gramont
Number of subjects: 48
Study 25824025 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal blockade
Number of subjects: 90
Study 25824025 — intervention group
Group type: COMPARATOR
Intervention: Single shot adductor canal blockade
Number of subjects: 90
Study 23364815 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 20
Study 23364815 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 20
Study 23364815 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 20
Study 23364815 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy volunteers)
Number of subjects: 20
Study 22193786 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practices model within the juvenile court system for early mental health intervention, including screening with the Youth Outcome Questionnaire and treatment involving psychiatric care and in-home behavioral intervention.
Number of subjects: 0
Study 22193786 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening at-risk teenagers with the Youth Outcome Questionnaire.
Number of subjects: 0
Study 19168876 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical variables (Step 1)
Number of subjects: 0
Study 19168876 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical measures (Step 2)
Number of subjects: 0
Study 19168876 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein and N-terminal pro B-type natriuretic peptide (Step 3)
Number of subjects: 0
Study 19168876 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 0
Study 17237661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (mean number of sessions 8.7+/‐2.9)
Number of subjects: 2564
Study 17237661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 2564
Study 17237661 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (employed patient subgroup analysis)
Number of subjects: 2564
Study 14742362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 80
Study 14742362 — intervention group
Group type: COMPARATOR
Intervention: Halothane anesthesia
Number of subjects: 80
Study 11682258 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.25 mg/70 kg)
Number of subjects: 15
Study 11682258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9625586 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V gene mutation testing
Number of subjects: 27
Study 9625586 — intervention group
Group type: COMPARATOR
Intervention: No factor V gene mutation
Number of subjects: 27
Study 1994682 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone
Number of subjects: 40
Study 1994682 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 1994682 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 40
Study 1994682 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 6093523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg intramuscularly
Number of subjects: 78
Study 6093523 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin 2.0 g intramuscularly
Number of subjects: 78
Study 6093523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 78
Study 6093523 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 78
Study 30758491 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Contacts (11 text messages delivered on day 1, week 1, and at months 1, 2, 3, 4, 6, 8, 10, and 12, plus birthdays)
Number of subjects: 658
Study 30758491 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring Contacts
Number of subjects: 658
Study 30758491 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 658
Study 29901295 — intervention group
Group type: EXPERIMENTAL
Intervention: EFFEX Tribulus
Number of subjects: 173
Study 29901295 — intervention group
Group type: COMPARATOR
Intervention: Tribestan
Number of subjects: 173
Study 27236082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sex hormone treatment (4 weeks and 4 months duration) in MtF and FtM transgender individuals
Number of subjects: 57
Study 27236082 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 male and 44 female)
Number of subjects: 57
Study 27236082 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment of MtF transgender individuals
Number of subjects: 57
Study 27236082 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy scores assessment
Number of subjects: 57
Study 23672386 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mL menthol gel
Number of subjects: 19
Study 23672386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 kg of crushed ice
Number of subjects: 19
Study 23672386 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mL of menthol gel and 0.5 kg of crushed ice
Number of subjects: 19
Study 23672386 — intervention group
Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 19
Study 23672386 — intervention group
Group type: EXPERIMENTAL
Intervention: menthol
Number of subjects: 19
Study 23672386 — intervention group
Group type: EXPERIMENTAL
Intervention: ice
Number of subjects: 19
Study 20615505 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made telemonitoring program
Number of subjects: 390
Study 19805781 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-hour seminar followed by three or four clinical sessions
Number of subjects: 86
Study 19805781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 86
Study 16755544 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method for estimating the distribution of time to tumour recurrence
Number of subjects: 0
Study 15476443 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (0.2 microg/kg)
Number of subjects: 2
Study 15476443 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (1 microg/kg)
Number of subjects: 2
Study 11491634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gates‐Glidden drills
Number of subjects: 100
Study 11491634 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Body Shapers
Number of subjects: 100
Study 10233876 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321 administered subcutaneously in divided doses of 135, 250, 500, 750, and 1,000 micrograms/m2/d during cycles 2 and later
Number of subjects: 49
Study 10233876 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321 administered during cycles A-2 and B-1
Number of subjects: 49
Study 10233876 — intervention group
Group type: EXPERIMENTAL
Intervention: PIXY321
Number of subjects: 49
Study 7982342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment with bronchodilators and anti-inflammatory agents
Number of subjects: 0
Study 7982342 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 0
Study 7982342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 0
Study 7982342 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive and nonconventional therapy
Number of subjects: 0
Study 7982342 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognosis of patients requiring mechanical ventilation
Number of subjects: 0
Study 2508467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation
Number of subjects: 0
Study 2508467 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure
Number of subjects: 0